FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback